Ubs Group Ag Xenon Pharmaceuticals Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Group Ag holds 13,290 shares of XENE stock, worth $516,050. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,290

Previous 12,578 5.66%

Holding current value

$516,050

Previous $490,000 6.53%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$36.12 - $43.96 $25,717 - $31,299	712 Added 5.66%	13,290 $522,000
Q2 2024 Aug 13, 2024	SELL	$36.25 - $43.75 $857,965 - $1.04 Million	-23,668 Reduced 65.3%	12,578 $490,000
Q1 2024 May 13, 2024	BUY	$42.66 - $50.04 $226,225 - $265,362	5,303 Added 17.14%	36,246 $1.56 Million
Q4 2023 Feb 09, 2024	BUY	$28.7 - $46.46 $719,250 - $1.16 Million	25,061 Added 426.06%	30,943 $1.43 Million
Q3 2023 Nov 09, 2023	BUY	$34.16 - $39.73 $34,262 - $39,849	1,003 Added 20.56%	5,882 $200,000
Q2 2023 Aug 11, 2023	BUY	$34.84 - $43.54 $9,232 - $11,538	265 Added 5.74%	4,879 $187,000
Q1 2023 May 12, 2023	SELL	$33.46 - $40.35 $1,606 - $1,936	-48 Reduced 1.03%	4,614 $165,000
Q4 2022 Feb 08, 2023	BUY	$33.06 - $39.43 $40,862 - $48,735	1,236 Added 36.08%	4,662 $183,000
Q3 2022 Nov 10, 2022	BUY	$30.79 - $39.82 $29,373 - $37,988	954 Added 38.59%	3,426 $123,000
Q2 2022 Aug 10, 2022	BUY	$25.44 - $35.16 $31,774 - $43,914	1,249 Added 102.13%	2,472 $76,000
Q1 2022 May 16, 2022	SELL	$25.09 - $33.13 $13,899 - $18,354	-554 Reduced 31.18%	1,223 $38,000
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $11,778 - $26,727	755 Added 73.87%	1,777 $56,000
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $14 - $19	1 Added 0.1%	1,022 $16,000
Q2 2021 Aug 13, 2021	BUY	$16.81 - $20.0 $353 - $420	21 Added 2.1%	1,021 $19,000
Q1 2021 May 12, 2021	SELL	$13.65 - $21.31 $9,855 - $15,385	-722 Reduced 41.93%	1,000 $18,000
Q4 2020 Feb 11, 2021	SELL	$9.49 - $16.04 $2,505 - $4,234	-264 Reduced 13.29%	1,722 $27,000
Q3 2020 Nov 12, 2020	SELL	$10.82 - $13.35 $3,116 - $3,844	-288 Reduced 12.66%	1,986 $22,000
Q2 2020 Jul 31, 2020	BUY	$10.21 - $14.9 $16,764 - $24,465	1,642 Added 259.81%	2,274 $29,000
Q1 2020 May 01, 2020	SELL	$8.08 - $17.57 $9,057 - $19,695	-1,121 Reduced 63.95%	632 $7,000
Q4 2019 Feb 14, 2020	BUY	$8.11 - $14.65 $4,233 - $7,647	522 Added 42.4%	1,753 $23,000
Q3 2019 Nov 14, 2019	SELL	$8.74 - $10.51 $34,016 - $40,904	-3,892 Reduced 75.97%	1,231 $11,000
Q2 2019 Aug 14, 2019	BUY	$8.51 - $10.75 $18,066 - $22,822	2,123 Added 70.77%	5,123 $51,000
Q1 2019 May 14, 2019	BUY	$6.39 - $10.42 $18,217 - $29,707	2,851 Added 1913.42%	3,000 $30,000
Q4 2018 Feb 14, 2019	SELL	$5.61 - $12.62 $3,955 - $8,897	-705 Reduced 82.55%	149 $1,000
Q3 2018 Nov 14, 2018	SELL	$9.0 - $14.9 $315 - $521	-35 Reduced 3.94%	854 $11,000
Q2 2018 Aug 14, 2018	BUY	$4.8 - $9.2 $4,267 - $8,178	889 New	889 $8,000
Q3 2017 Nov 14, 2017	SELL	$2.45 - $3.25 $6,198 - $8,222	-2,530 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	2,530	2,530 $8,000

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account